Literature DB >> 20038196

Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.

Marina S Boukhvalova1, Talia B Sotomayor, Ryan C Point, Lioubov M Pletneva, Gregory A Prince, Jorge C G Blanco.   

Abstract

Interferon (IFN) therapy in humans often causes flu-like symptoms by an unknown mechanism. Poly ICLC is a synthetic dsRNA and a Toll-like receptor 3 (TLR3) agonist with a strong IFN-inducing ability. In this work, we analyzed the effect of poly ICLC on pulmonary responses to influenza and respiratory syncytial virus (RSV) infections in the cotton rat (Sigmodon hispidus) model. Viral replication, pulmonary inflammation, and expression of IFN, TLR, and chemokines were monitored and compared. Antiviral effect of poly ICLC against influenza virus and RSV was best achieved at high poly ICLC concentrations that, in the absence of virus infection, induced a strong IFN response. The antiviral doses of poly ICLC, however, also increased lung inflammation, an unexpected finding because of the reported poly ICLC safety in BALB/c mice. Similarly, in contrast to murine model, pathology of RSV infection was increased in cotton rats treated with poly ICLC. Augmented lung inflammation was accompanied by an earlier induction of IFN and TLR responses and a stronger chemokine expression. Overall, these findings indicate significant association between antiviral IFN action and pulmonary inflammation and highlight important animal model-specific variations in the potential of IFN to cause pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20038196      PMCID: PMC2882628          DOI: 10.1089/jir.2009.0025

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  56 in total

1.  Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism.

Authors:  Caroline A Lindemans; Paul J Coffer; Ingrid M M Schellens; Patricia M A de Graaff; Jan L L Kimpen; Leo Koenderman
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction.

Authors:  Murali Ramaswamy; Lei Shi; Steven M Varga; Sailen Barik; Mark A Behlke; Dwight C Look
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

3.  Role for innate IFNs in determining respiratory syncytial virus immunopathology.

Authors:  Teresa R Johnson; Sara E Mertz; Negin Gitiban; Sue Hammond; Robin Legallo; Russell K Durbin; Joan E Durbin
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

4.  Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells.

Authors:  Ping Liu; Mohammad Jamaluddin; Kui Li; Roberto P Garofalo; Antonella Casola; Allan R Brasier
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 5.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.

Authors:  Loïc Guillot; Ronan Le Goffic; Sarah Bloch; Nicolas Escriou; Shizuo Akira; Michel Chignard; Mustapha Si-Tahar
Journal:  J Biol Chem       Date:  2004-12-03       Impact factor: 5.157

7.  Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis.

Authors:  Jennifer L Reed; Yambasu A Brewah; Tracy Delaney; Timothy Welliver; Timothy Burwell; Ebony Benjamin; Ellen Kuta; Alexander Kozhich; LuAnn McKinney; JoAnn Suzich; Peter A Kiener; Luis Avendano; Luis Velozo; Alison Humbles; Robert C Welliver; Anthony J Coyle
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

8.  Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections.

Authors:  Tim R Traynor; Jeannine A Majde; Stewart G Bohnet; James M Krueger
Journal:  Life Sci       Date:  2004-04-02       Impact factor: 5.037

9.  Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo.

Authors:  Nancy A Jewell; Negin Vaghefi; Sara E Mertz; Parvis Akter; R Stokes Peebles; Lauren O Bakaletz; Russell K Durbin; Emilio Flaño; Joan E Durbin
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

10.  Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats.

Authors:  Lioubov M Pletneva; Otto Haller; David D Porter; Gregory A Prince; Jorge C G Blanco
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

View more
  18 in total

1.  Negative control of TLR3 signaling by TICAM1 down-regulation.

Authors:  Shasha Tao; Lingxiang Zhu; Pakkei Lee; Wai-ming Lee; Kenneth Knox; Jie Chen; Yuanpu Peter Di; Yin Chen
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 2.  Toll like receptors in diseases of the lung.

Authors:  Melissa A Kovach; Theodore J Standiford
Journal:  Int Immunopharmacol       Date:  2011-05-30       Impact factor: 4.932

Review 3.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

Review 4.  Systems biology unravels interferon responses to respiratory virus infections.

Authors:  Andrea L Kroeker; Kevin M Coombs
Journal:  World J Biol Chem       Date:  2014-02-26

Review 5.  Animal models of human respiratory syncytial virus disease.

Authors:  Reinout A Bem; Joseph B Domachowske; Helene F Rosenberg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

6.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

7.  Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.

Authors:  David Olagnier; Florine E M Scholte; Cindy Chiang; Irina C Albulescu; Carmen Nichols; Zhong He; Rongtuan Lin; Eric J Snijder; Martijn J van Hemert; John Hiscott
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

Review 8.  Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells.

Authors:  Zhaoduan Liang; Siyu Wu; Yuye Li; Li He; Minhao Wu; Lifang Jiang; Lianqiang Feng; Ping Zhang; Xi Huang
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

Review 10.  Current concepts and progress in RSV vaccine development.

Authors:  Aleks K Guvenel; Christopher Chiu; Peter Jm Openshaw
Journal:  Expert Rev Vaccines       Date:  2014-01-09       Impact factor: 5.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.